FDA Approves Drug to Limit Toilet Trips During Night

The US Food and Drug Administration (FDA) has approved a treatment for adults who wake up to urinate at least twice during the night.

FDA said it has approved Noctiva nasal spray only for adults with nocturia caused by nocturnal polyuria -- overproduction of urine during the night.

FDA-Approved Supplement Improves Survival in Mouse Model of Amyotrophic Lateral Sclerosis
A bacterial by-product known to be important in maintaining gut health may slow the progression of amyotrophic lateral sclerosis.

‘Nocturia (waking at night to urinate) can be caused by a range of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.’

Tweet it Now

"Today’s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate," Hylton V. Joffe from FDA’s Center for Drug Evaluation and Research said in a statement on Friday.

"It is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them," Joffe added.

Nocturia (waking at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.

Cholesterol-Lowering Pitavastatin Tablet Gets USFDA Approval
Pitavastatin tablets to reduce cholesterol has received tentative approval from the United States Food and Drug Administration (USFDA).

Noctiva is taken daily, approximately 30 minutes before going to bed.

It works by increasing the absorption of water through the kidneys, which leads to less urine production.

United States FDA Approves Diabetes Drug Jardiance to Reduce Cardiovascular Disease
Jardiance can now be prescribed to reduce the risk of cardiovascular death in adult patients with Type-2 diabetes and cardiovascular disease.

Noctiva’s efficacy was established in two 12-week, randomised, placebo-controlled trials on 1,045 patients 50 years of age and older with nocturia due to nocturnal polyuria.

Although these trials showed a small reduction in the average number of night-time urinations with Noctiva compared to placebo, more patients treated with Noctiva were able to at least halve their number of night-time urinations, and patients treated with Noctiva had more nights with one or fewer night-time urinations.

New Drug Combo To Treat Adult Sarcoma Gets FDA Approval
Adding the new targeted antibody olaratumab (Lartruvo) in combination with doxorubicin improves progression-free survival in patients with advanced sarcomas.

The most common side effects of Noctiva in clinical trials included nasal discomfort, cold symptoms (nasopharyngitis), nasal congestion, sneezing, high or increased blood pressure, back pain, nose bleeds, bronchitis and dizziness.

Noctiva is marketed by Milford, Pennsylvania-based Renaissance Lakewood, LLC for Serenity Pharmaceuticals, LLC.

Source-IANS